CL2016003131A1 - Composiciones de omega-3, formas de dosis, y métodos de uso - Google Patents

Composiciones de omega-3, formas de dosis, y métodos de uso

Info

Publication number
CL2016003131A1
CL2016003131A1 CL2016003131A CL2016003131A CL2016003131A1 CL 2016003131 A1 CL2016003131 A1 CL 2016003131A1 CL 2016003131 A CL2016003131 A CL 2016003131A CL 2016003131 A CL2016003131 A CL 2016003131A CL 2016003131 A1 CL2016003131 A1 CL 2016003131A1
Authority
CL
Chile
Prior art keywords
compositions
dosage forms
omega
methods
epa
Prior art date
Application number
CL2016003131A
Other languages
English (en)
Inventor
Olav Sandnes
Bruce A Miller
Jorn Dyerberg
Steen Stender
Original Assignee
Marine Ingredients Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Ingredients Llc filed Critical Marine Ingredients Llc
Publication of CL2016003131A1 publication Critical patent/CL2016003131A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

<p>Se describen en la presente las composiciones de omega-3, las formas de dosis, y los métodos de uso. Las composiciones y formas de dosis de omega-3 descritas en la presente pueden comprenden DHA y EPA a una proporción de aproximadamente 3:2. Las composiciones y formas de dosis de omega-3 descritas en la presente pueden comprender triglicéridos re-esterificados. Se describen también los métodos de tratamiento utilizados en las composiciones y las formas de dosis.</p>
CL2016003131A 2014-06-06 2016-12-05 Composiciones de omega-3, formas de dosis, y métodos de uso CL2016003131A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US201462019289P 2014-06-30 2014-06-30

Publications (1)

Publication Number Publication Date
CL2016003131A1 true CL2016003131A1 (es) 2017-06-09

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003131A CL2016003131A1 (es) 2014-06-06 2016-12-05 Composiciones de omega-3, formas de dosis, y métodos de uso

Country Status (14)

Country Link
US (4) US9675575B2 (es)
EP (2) EP3906920A1 (es)
JP (2) JP6755186B2 (es)
KR (1) KR102400958B1 (es)
CN (1) CN106687113B (es)
AU (1) AU2015269307C1 (es)
BR (1) BR112016028561A8 (es)
CA (1) CA2950344C (es)
CL (1) CL2016003131A1 (es)
MX (1) MX2016015791A (es)
MY (1) MY186566A (es)
RU (1) RU2741965C2 (es)
TW (1) TWI725937B (es)
WO (1) WO2015188046A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
RU2741965C2 (ru) 2014-06-06 2021-02-01 Мэрин Ингридиэнтс, Ллк Композиции c омега-3, лекарственные формы и способы их применения
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
CA2236089C (en) * 1995-11-24 2002-03-05 Loders-Croklaan B.V. Composition based on fish oil
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
WO2007066232A2 (en) 2005-10-07 2007-06-14 Ocean Nutrition Canada Ltd. Salts of fatty acids and methods of making and using thereof
WO2007075841A1 (en) 2005-12-20 2007-07-05 Cenestra, Llc Omega 3 fatty acid formulations
EP1962825B1 (en) 2005-12-21 2014-04-02 Brudy Technology, S.L. Use of dha for treating a pathology associated with cellular oxidative damage
US20070298156A1 (en) 2006-06-23 2007-12-27 Haile Mehansho Concentrated omega-3 fatty acids and mixtures containing them
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
WO2008133573A1 (en) * 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
WO2009017102A1 (ja) * 2007-07-30 2009-02-05 Nippon Suisan Kaisha, Ltd. Epa濃縮油およびdha濃縮油の製造方法
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
PL2323647T3 (pl) * 2008-08-07 2015-03-31 Spa Soc Prodotti Antibiotici S P A Długotrwałe leczenie objawowej niewydolności serca
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
EP2405902B1 (en) * 2009-03-09 2021-07-21 Basf As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
EP2560633B8 (en) 2010-04-23 2020-08-12 The Government of the United States, as represented by The Secretary of the Army Intravenous omega-3 fatty acid compositions & method of use
US9145533B2 (en) * 2010-09-24 2015-09-29 Pronova Blopharm Norge AS Process for concentrating omega-3 fatty acids
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
WO2013086323A2 (en) * 2011-12-08 2013-06-13 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
CN116173001A (zh) 2012-05-10 2023-05-30 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
EP2897595B1 (en) 2012-09-24 2020-06-03 Aker Biomarine Antarctic As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
RU2741965C2 (ru) * 2014-06-06 2021-02-01 Мэрин Ингридиэнтс, Ллк Композиции c омега-3, лекарственные формы и способы их применения

Also Published As

Publication number Publication date
CN106687113B (zh) 2021-09-03
TW201613571A (en) 2016-04-16
US9675575B2 (en) 2017-06-13
CA2950344C (en) 2023-09-19
AU2015269307B2 (en) 2019-03-14
US20170252313A1 (en) 2017-09-07
MX2016015791A (es) 2017-05-30
JP6755186B2 (ja) 2020-09-16
TWI725937B (zh) 2021-05-01
AU2015269307A1 (en) 2017-01-05
BR112016028561A8 (pt) 2021-06-29
RU2016149416A (ru) 2018-07-10
EP3906920A1 (en) 2021-11-10
BR112016028561A2 (pt) 2017-08-22
JP2017516811A (ja) 2017-06-22
US11160777B2 (en) 2021-11-02
EP3151826A4 (en) 2018-01-24
CA2950344A1 (en) 2015-12-10
MY186566A (en) 2021-07-27
CN106687113A (zh) 2017-05-17
JP2020105224A (ja) 2020-07-09
WO2015188046A1 (en) 2015-12-10
AU2015269307C1 (en) 2019-10-03
KR102400958B1 (ko) 2022-05-20
US20160243068A1 (en) 2016-08-25
EP3151826A1 (en) 2017-04-12
RU2016149416A3 (es) 2018-12-05
US10034849B2 (en) 2018-07-31
KR20170018825A (ko) 2017-02-20
RU2741965C2 (ru) 2021-02-01
US20210308086A1 (en) 2021-10-07
US20180303784A1 (en) 2018-10-25
US10172819B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2018000897A1 (es) Composicion de fortalecimiento del cabello y metodo para fortalecer el cabello.
AR100155A1 (es) Composiciones de insulina y treprostinil de rápida acción
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
PE20151894A1 (es) Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp 3)
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CL2015002897A1 (es) Inhibidores de bace1
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2016003131A1 (es) Composiciones de omega-3, formas de dosis, y métodos de uso
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas